Molecular
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 2004-01-01
- Employees
- 167
- Market Cap
- $229.6M
- Introduction
Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to address existing limitations of antibody drugs. The company products include Abicipar, MP0250/MP0274 and Clinical Trials. The company was founded by Christian Zahnd, Patrick Amstutz, Patrik Forrer, Andreas Plückthun, and Michael Tobias Stumpp on November 22, 2004 and is headquartered in Schlieren, Switzerland.
Hepatocyte Growth Factors Market Insights into Therapeutic Potential Across Multiple Diseases
The HGF market, valued at US$ 70.3 million in 2023, is projected to reach US$ 141.0 million by 2034, driven by demand for regenerative medicine, biotech advancements, and HGF applications in liver regeneration, oncology, wound healing, and tissue repair.
Personalized Medicines Market to Surpass Valuation of USD
SkyQuest projects the global personalized medicines market to reach USD 1352.81 Billion by 2031, with a CAGR of 11.40% driven by innovative therapies, partnerships, and advancements in genomics and AI-powered diagnostics. North America leads due to favorable regulatory frameworks and high R&D spending.
Biotechnology Value Fund L P's Strategic Acquisition in Molecula
Biotechnology Value Fund L P acquired 1,192,387 shares of Molecular Partners AG, increasing its stake to 9,888,592 shares. The firm's investment strategy focuses on biotechnology, leveraging scientific assessment and financial analysis. Molecular Partners AG, with a market cap of $221.27 million, specializes in DARPin therapeutics for diseases like cancer. The acquisition reflects Biotechnology Value Fund L P's confidence in the company's potential.
© Copyright 2025. All Rights Reserved by MedPath